OBJECTIVES: This retrospective, panel-based online physician chart review assessed effectiveness of quarterly and monthly fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), for reducing monthly migraine days (MMD) and monthly headache days (MHD) in adult migraine patients up to 6 months.

METHODS: This panel-based chart review used electronic case report forms. Patient inclusion criteria were physician-diagnosed chronic migraine (CM) or episodic migraine (EM); fremanezumab treatment initiation at ≥18 years of age after FDA approval (initiation, October 2, 2018–July 17, 2020); ≥1 dose of fremanezumab treatment; and ≥2 MMD assessments (1 within 30 days before and ≥1 after initiation).

RESULTS: Data from 421 clinicians and 1,003 patients were used. For patients receiving quarterly (n=381) and monthly (n=622) dosing, respectively, mean age at initiation was 39.4 and 39.8 years; 71% and 79% of patients were female. With quarterly and monthly dosing, respectively, mean baseline MMD were 11.9 and 13.2, and MHD were 12.9 and 14.8 (both P≤0.002 for quarterly vs monthly). Both doses provided sustained reductions in MHD and MMD. Changes from baseline generally did not differ significantly for quarterly versus monthly dosing for MMD at Month 1 (mean [percent reduction]: –3.9 [32.8%] vs –4.9 [37.1%]; P=0.200 for quarterly vs monthly), Month 3 (–6.2 [52.1%] vs –7.2 [54.5%]; P=0.116 for quarterly vs monthly), or Month 6 (–9.5 [79.8%] vs –8.9 [67.4%]; P=0.643 for quarterly vs monthly) or for MHD at Month 1 (–3.7 [28.7%] and –5.1 [34.5%]; P=0.082 for quarterly vs monthly), Month 3 (–6.0 [46.5%] vs –7.7 [52.0%]; P=0.021 for quarterly vs monthly), or Month 6 (–9.7 [75.2%] vs –9.8 [66.2%]; P=0.908 for quarterly vs monthly).

CONCLUSIONS: In this real-world study, both quarterly and monthly fremanezumab resulted in clinically meaningful reductions in MMD and MHD up to 6 months.